Oncology Data Advisor is excited to be launching our new podcast series, "Exploring Artificial Intelligence in Oncology." Hosted by Waqas Haque, MD, MPH, Member of the Oncology Data Advisor Fellows Forum, this series will delve into the burgeoning roles and uses of AI in cancer care, from pathology to toxicity risk prediction to treatment recommendations and beyond.

Exploring Artificial Intelligence in Oncology

In this first episode of Oncology Data Advisor’s new podcast series, “Exploring Artificial Intelligence in Cancer Care,” Dr. Waqas Haque and Dr. Matthew Hadfield of the OncData Fellows Forum engage in a discussion with Dr. Ofer Sharon, CEO of OncoHost. Dr. Sharon provides an overview of the clinical need for increased knowledge of patients’ probabilities of developing immune-related adverse events and explains the PROphet® platform, OncoHost’s novel plasma-based, proteomic pattern analysis tool that uses a single blood sample to guide immunotherapy treatment decisions.

Predicting Immune-Related Adverse Events Through Machine Learning With Dr. Ofer Sharon of OncoHost

This second episode of Oncology Data Advisor's podcast series, Exploring Artificial Intelligence in Oncology, features Leif Honda, Chief Innovation Officer at TriMetis, a digital pathology company focused on improving patient outcomes by accelerating human tissue-based research, development, and testing. Dr. Waqas Haque, member of the Oncology Data Advisor Fellows Forum, speaks with Mr. Honda about the TriMetis Computer-Assisted Pathology (TCAP) AI platform, including how it was developed and trained, its capabilities for streamlining the pathology workflow, and the ongoing process of preparing it for clinical utility.

Streamlining the Pathology Workflow Through AI: Waqas Haque and Leif Honda of TriMetis

In this installment of Oncology Data Advisor's Exploring AI in Oncology series, Dr. Waqas Haque speaks with Dr. Shaalan Beg, an Adjunct Associate Professor at the University of Texas (UT) Southwestern, who is spearheading efforts to decentralize clinical trials in oncology and expand access for eligible patients. Dr. Beg describes the tools that are currently in development for decentralizing trials, including the use of artificial intelligence (AI), natural language processing, and telehealth. Additionally, he shares his perspectives on transitioning to a career in industry.

Expanding Clinical Trial Access With Decentralization and Technology: Waqas Haque and Shaalan Beg

In this installment of Oncology Data Advisor's Exploring Artificial Intelligence in Oncology series, Dr. Waqas Haque, Fellows Forum member and incoming Hematology/Oncology Fellow at the University of Chicago, speaks with Tracey Sikora, Co-Founder of Every Cure, a nonprofit organization whose mission is to repurpose existing FDA-approved drugs for other indications, especially in rare diseases. 

Check out the discussion to learn more about: 
•	Challenges in finding treatments for rare diseases, including sparse data, low patient numbers, and lack of financial incentive for pharmaceutical companies
•	Every Cure’s mission to unlock the potential of drugs that are already on the market
•	Harnessing the latest AI and machine learning technology to structure data in a biomedical knowledge graph, looking at drugs, diseases, pathways, and targets
•	Barriers in drug repurposing, including clinical validation and eventual approval
•	The Advanced Research Projects Agency for Health (ARPA-H) grant and the importance of federal funding for rare disease research
•	How to develop efficient clinical trials without a large sample size
•	The future of AI-enabled drug discovery in oncology 
•	And more!

Every Cure: Unlocking Drug Potential With Artificial Intelligence With Waqas Haque and Tracey Sikora

This installment of Oncology Data Advisor's Exploring Artificial Intelligence (AI) in Oncology series features a discussion recorded live at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting between Ranjana Devi, Vice President of Product Development, Oncology, at Qure.ai, and Fellows Forum member Dr. Waqas Haque. 

Check out the episode to hear more about: 
•	Qure.ai’s mission of making healthcare more accessible and equitable to patients worldwide through innovations in deep learning and AI
•	Current challenges in lung cancer screening and the capabilities of AI in addressing these gaps
•	Qure.ai’s end-to-end AI-powered solutions for early lung cancer detection and care
•	The efficacy of these solutions and how they can be used in the clinic
•	The lung cancer portfolio that Qure.ai showcased at ASCO
•	Other innovations coming down the pipeline
•	And more!

Qure.ai: Improving Early Lung Cancer Detection Through AI with Ranjana Devi and Waqas Haque, MD, MPH

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Dr. Tamir Wolf, Co-Founder and CEO of Theator, a company pioneering next-generation AI and computer vision technology to automatically capture and analyze surgical data in real time to generate actionable insights and improve surgical outcomes.

Reimagining Surgery Through AI and Computer Vision Technology: Dr. Tamir Wolf and Dr. Waqas Haque

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque sits down with Luis Valente, CEO and Co-Founder of iLoF, a digital health company pioneering a breakthrough AI platform to accelerate the future of personalized drug discovery and development.

The Digital Fingerprint: Accelerating Personalized Drug Discovery and Development at iLoF

In this episode of Exploring Artificial Intelligence (AI) in Oncology, Dr. Waqas Haque sits down with Dana Brown, the President, CEO, and Chairman of the Board at iCAD, a company whose mission is to use innovative AI solutions that empower providers to accurately, reliably, and quickly detect cancer and improve outcomes. Ms. Brown shares more about iCAD’s products and recommendations for how to integrate AI into the clinic, including: 

•	Her own background in the technology industry and why she joined iCAD
•	The products and solutions that iCAD offers
•	How iCAD utilizes AI to improve mammography accuracy
•	The ProFound Breast Health Suite and how it enhances cancer detection and patient outcomes
•	Their recent partnership with Densitas and CancerIQ and their impact on breast health
•	What distinguishes iCAD’s AI algorithms from other solutions in the market
•	The importance of company culture in driving success of AI startups and defining traits behind iCAD’s success
•	Recommendations for clinicians in practice to learn about and integrate AI into their workflow
•	And more!

iCAD: Creating a World Where Cancer Can’t Hide  With Waqas Haque, MD, MPH, and Dana Brown

In this episode of Exploring Artificial Intelligence in Oncology, Dr. Waqas Haque, MD, sits down with Aamir Ehsan, MD, the Founder and CEO of CorePath Laboratories in San Antonio, Texas. Together they discuss how CorePath utilizes AI in pathology.

Revolutionizing Cancer Diagnostics Through AI-Powered Analysis: CorePath

Artera: Personalizing Treatment Decisions in Prostate Cancer and Beyond With Waqas Haque, MD, MPH, and Trevor Royce, MD, MS, MPH, FASCO

In this episode of Exploring Artificial Intelligence in Oncology, Wanmei Ou, PhD, the Vice President of Product, Clinical Decision Support, & Analytics Data Platform at Ontada, shares more about Ontada’s collaboration with Microsoft to transform unstructured oncology data with Azure OpenAI technology. Her discussion with Dr. Waqas Haque highlights how AI is transforming clinical workflows, reducing documentation burdens, and driving improved patient outcomes.

Learn more at: https://oncdata.com/ontada-microsoft-azure-ai-real-world-data-processing-in-oncology/

Ontada, Microsoft, and Azure AI: Collaborating to Transform Real-Word Data Processing in Oncology

Artificial Intelligence (AI) is revolutionizing healthcare, and oncology is no exception. In this episode of the Exploring AI in Oncology series, Kristin Maloney, MS, BSN, RN, OCN®, a Certified Oncology Nurse and the Clinical Informatics Lead at Mendel AI, speaks with Dr. Waqas Haque on how AI can address some of the biggest challenges in oncology. She shares more about Mendel’s innovative platform, which leverages physician-level cognitive capabilities to enhance data process and improve clinical decision making and patient outcomes. 

Learn more at: https://oncdata.com/mendel-ai-with-kristin-maloney 


Mendel AI: Enhancing Clinical Data Processing for Empowered Clinical Decision Making With Kristin Maloney, MS, BSN, RN, OCN®, and Waqas Haque, MD, MPH

In this episode of the Exploring Artificial Intelligence (AI) in Oncology series, Waqas Haque, MD, MPH, Hematology/Oncology Fellow at the University of Chicago, speaks with Osama Khan, MD, Staff Pathologist at Natera, a cell-free DNA (cfDNA) technology company that aims to make personalized genetic testing and diagnostics part of the standard of care. Dr. Khan shares insights into how digital pathology and emerging technologies like AI and measurable residual disease (MRD) testing are revolutionizing oncology, driving precision medicine, and enhancing patient care.

Learn more at: https://oncdata.com/digital-pathology-osama-khan 

From Glass Slides to AI: How Digital Pathology and MRD Testing Are Transforming Cancer Care With Osama Khan, MD, and Waqas Haque, MD, MPH

In this episode of the Exploring AI in Oncology podcast, Waqas Haque, MD, MPH, a Hematology/Oncology Fellow at the University of Chicago, speaks with Samir Shah, MD, MMM, FACR, the Chief Medical Officer at Qure.ai. Their discussion explores how Qure.ai’s innovative AI solutions are addressing critical gaps in lung cancer screening and improving early detection through advanced image analysis and clinical data integration.

Harnessing AI for Early Lung Cancer Detection: Qure.ai’s Innovations and Impact

Read the full article here: https://oncdata.com/reimagining-oncology-nursing-through-ai  

In this episode of the Exploring AI in Oncology series, Dr. Waqas Haque, Hematology/Oncology Fellow at the University of Chicago, spoke with Kathleen McGrow, Sangeeta Agarawal, and Marc Perkins-Carrillo about their presentation at the Oncology Nursing Society (ONS) Congress about the intersection of artificial intelligence (AI) and oncology nursing. Their conversation highlights the transformative potential of AI in nursing, the skills needed to navigate this evolving landscape, and the ethical considerations that must guide its implementation.

Reimagining Oncology Nursing Through AI Innovations: Waqas Haque, Kathleen McGrow, Sangeeta Agarawal, Marc Perkins-Carrillo

Read the full article for this interview here: https://oncdata.com/standard-model-biomedicine 

Artificial intelligence (AI) is rapidly transforming the landscape of oncology, offering new tools to improve patient care and accelerate research. In this episode of Exploring AI in Oncology, Dr. Waqas Haque sat down with Kevin Brown, Founder and CEO of Standard Model Biomedicine, to discuss the challenges and opportunities of implementing AI in cancer care.


Building Effective AI Foundation Models at Standard Model Biomedicine With Kevin Brown and Waqas Haque, MD, MPH

A Return on Humanity: How the American Cancer Society Uses AI to Improve Patient Care

The mission of Oncology Data Advisor is to provide the multidisciplinary team with expert insights into clinical best practices and research progress in cancer care.

Exploring Artificial Intelligence in Oncology

Oncology Data Advisor®